VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 22, 2015, Pages E2900-E2909

  Yang, Xiaojuan ^a,b   Zhang, Yin ^a   Hosaka, Kayoko ^a   Andersson, Patrik ^a   Wang, Jian ^a   Tholander, Fredrik ^a   Cao, Ziquan ^c   Morikawa, Hiromasa ^a   Tegnér, Jesper ^a   Yang, Yunlong ^a   Iwamoto, Hideki ^a   Lim, Sharon ^a   Cao, Yihai ^a,c,d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TONGJI UNIVERSITY   (China)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Metastasis; VEGF A; VEGF B; VEGFR1

Indexed keywords

MESSENGER RNA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; TUMOR MARKER; VASCULAR ENDOTHELIAL GROWTH FACTOR B, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; GENE DELETION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MOUSE; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINOBLASTOMA; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; VASCULAR REMODELING; ZEBRA FISH; ANIMAL; CELL HYPOXIA; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; KAPLAN MEIER METHOD; METABOLISM; MICROVASCULATURE; NEOPLASM; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULARIZATION; WESTERN BLOTTING;

MUS;

ANIMALS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL HYPOXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; MICE; MICROVESSELS; NEOPLASM METASTASIS; NEOPLASMS; POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR B; ZEBRAFISH;

EID: 84930941341     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1503500112     Document Type: Article

References (43)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
2. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285(21):1182-1186.
3. Cao Y, et al. (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3(114):114rv3.
4. Cao Y, Langer R (2010) Optimizing the delivery of cancer drugs that block angiogenesis. Sci Transl Med 2(15):ps3.
5. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342.
6. Lees CW, Ironside J, Wallace WA, Satsangi J (2008) Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 359(3):320-321.
7. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239-252.
8. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71-78.
9. Psaila B, Lyden D (2009) The metastatic niche: Adapting the foreign soil. Nat Rev Cancer 9(4):285-293.
10. Gupta GP, Massagué J (2006) Cancer metastasis: Building a framework. Cell 127(4):679-695.
11. Jubb AM, et al. (2004) Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57(5):504-512.
12. Cao Y, Liu Q (2007) Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 97:203-224.
13. Kim KJ, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841-844.
14. Senger DR, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985.
15. Sawamiphak S, et al. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465(7297):487-491.
16. Cao Y (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2(59):re1.
17. Shibuya M (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): A dual regulator for angiogenesis. Angiogenesis 9(4):225-230, discussion 231.
18. Olofsson B, et al. (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93(6):2576-2581.
19. Li X, et al. (2009) VEGF-B: A survival, or an angiogenic factor? Cell Adhes Migr 3(4):322-327.
20. Albrecht I, et al. (2010) Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 5(11):e14109.
21. Zhang F, et al. (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106(15):6152-6157.
22. Rouhi P, et al. (2010) Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc 5(12):1911-1918.
23. Lee SL, et al. (2009) Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci USA 106(46):19485-19490.
24. Dahl Ejby Jensen L, et al. (2009) Nitric oxide permits hypoxia-induced lymphatic perfusion by controlling arterial-lymphatic conduits in zebrafish and glass catfish. Proc Natl Acad Sci USA 106(43):18408-18413.
25. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248(2):307-318.
26. Viloria-Petit A, et al. (2003) Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 22(16):4091-4102.
27. Yang Y, et al. (2013) Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci USA 110(29):12018-12023.
28. Hedlund EM, et al. (2013) Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 110(2):654-659.
29. Yang X, et al. (2013) Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA 110(34):13932-13937.
30. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95(16):9349-9354.
31. Rouhi P, et al. (2010) Pathological angiogenesis facilitates tumor cell dissemination and metastasis. Cell Cycle 9(5):913-917.
32. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62.
33. Schomber T, et al. (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67(22):10840-10848.
34. Xu L, et al. (2006) Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 66(8):3971-3977.
35. Eriksson A, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1(1):99-108.
36. Fischer C, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3):463-475.
37. Makino Y, et al. (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414(6863):550-554.
38. Mandriota SJ, et al. (2002) HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1(5):459-468.
39. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367(6463):576-579.
40. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843-845.
41. Arbiser JL, Bips M, Seidler A, Bonner MY, Kovach C (2012) Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol 67(2):e81-e83.
42. Bonner MY, Arbiser JL (2014) The antioxidant paradox: What are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem 6(12):1413-1422.
43. Munson JM, et al. (2012) Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 4(127):127ra36.